Simultaneously Inhibiting BCL2 and MCL1 Is a Therapeutic Option for Patients with Advanced Melanoma

Targeting MCL-1 in hematologic malignancies: Rationale and progress

(2020) AndrewH. Wei et al.   BLOOD REVIEWS

Inhibiting Translation Elongation with SVC112 Suppresses Cancer Stem Cells and Inhibits Growth in Head and Neck Squamous Carcinoma

(2020) Stephen B. Keysar et al.   CANCER RESEARCH

Dual targeting of BCL2 and MCL1 rescues myeloma cells resistant to BCL2 and MCL1 inhibitors associated with the formation of BAX/BAK hetero-complexes

(2020) Carolane Seiller et al.   Cell Death & Disease

Bim, Puma and Noxa upregulation by Naftopidil sensitizes ovarian cancer to the BH3-mimetic ABT-737 and the MEK inhibitor Trametinib

(2020) Romane Florent et al.   Cell Death & Disease

MCL1 inhibitors S63845/MIK665 plus Navitoclax synergistically kill difficult-to-treat melanoma cells

(2020) Nabanita Mukherjee et al.   Cell Death & Disease

BH3 mimetics: Weapons of cancer cell destruction

(2019) Tríona Ní Chonghaile   Science Translational Medicine

Recent advances in the development of Mcl-1 inhibitors for cancer therapy

(2019) Alexander W. Hird et al.   PHARMACOLOGY & THERAPEUTICS

Cotargeting of BCL2 with Venetoclax and MCL1 with S63845 Is Synthetically Lethal In Vivo in Relapsed Mantle Cell Lymphoma

(2019) Dana Prukova et al.   CLINICAL CANCER RESEARCH

BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival

(2019) Erinna F. Lee et al.   Cell Death & Disease

Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma

(2019) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combination of fenretinide and ABT-263 induces apoptosis through NOXA for head and neck squamous cell carcinoma treatment

(2019) Erin L. Britt et al.   PLoS One

Proteomics of Melanoma Response to Immunotherapy Reveals Mitochondrial Dependence

(2019) Michal Harel et al.   CELL

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

(2019) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Venetoclax: A Review in Relapsed/Refractory Chronic Lymphocytic Leukemia

(2019) Lesley J. Scott   Targeted Oncology

Side-by-side comparison of BH3-mimetics identifies MCL-1 as a key therapeutic target in AML

(2019) Larissa Ewald et al.   Cell Death & Disease

The MCL1-specific inhibitor S63845 acts synergistically with venetoclax/ABT-199 to induce apoptosis in T-cell acute lymphoblastic leukemia cells

(2018) Zhaodong Li et al.   LEUKEMIA

Targeting melanoma stem cells with the Vitamin E derivative δ-tocotrienol

(2018) Monica Marzagalli et al.   Scientific Reports

Microenvironment-Driven Dynamic Heterogeneity and Phenotypic Plasticity as a Mechanism of Melanoma Therapy Resistance

(2018) Farzana Ahmed et al.   Frontiers in Oncology

Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia

(2018) Donia M. Moujalled et al.   LEUKEMIA

BH3 mimetics induce apoptosis independent of DRP-1 in melanoma

(2018) Nabanita Mukherjee et al.   Cell Death & Disease

Characterization and targeting of malignant stem cells in patients with advanced myelodysplastic syndromes

(2018) Brett M. Stevens et al.   Nature Communications

AMG 176, a Selective MCL1 Inhibitor, is Effective in Hematological Cancer Models Alone and in Combination with Established Therapies

(2018) Sean Caenepeel et al.   Cancer Discovery

NOXA genetic amplification or pharmacologic induction primes lymphoma cells to BCL2 inhibitor-induced cell death

(2018) Yuxuan Liu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia

(2018) Adriana E. Tron et al.   Nature Communications

Whole-exome sequencing identifies recurrent SF3B1 R625 mutation and comutation of NF1 and KIT in mucosal melanoma

(2017) Jennifer D. Hintzsche et al.   MELANOMA RESEARCH

Down-Regulation of SOX2 Underlies the Inhibitory Effects of the Triphenylmethane Gentian Violet on Melanoma Cell Self-Renewal and Survival

(2016) Silvia Pietrobono et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models

(2016) András Kotschy et al.   NATURE

Combining a GSI and BCL-2 inhibitor to overcome melanoma’s resistance to current treatments

(2016) Nabanita Mukherjee et al.   Oncotarget

Use of a MCL-1 inhibitor alone to de-bulk melanoma and in combination to kill melanoma initiating cells

(2016) Nabanita Mukherjee et al.   Oncotarget

High efficacy of the BCL-2 inhibitor ABT199 (venetoclax) in BCL-2 high-expressing neuroblastoma cell lines and xenografts and rational for combination with MCL-1 inhibition

(2016) Laurel T. Bate-Eya et al.   Oncotarget

Genomic Classification of Cutaneous Melanoma

(2015) Rehan Akbani et al.   CELL

The BCL-2 protein family, BH3-mimetics and cancer therapy

(2015) A R D Delbridge et al.   CELL DEATH AND DIFFERENTIATION

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

(2015) Dirk Schadendorf et al.   JOURNAL OF CLINICAL ONCOLOGY

Combining a BCL2 Inhibitor with the Retinoid Derivative Fenretinide Targets Melanoma Cells Including Melanoma Initiating Cells

(2015) Nabanita Mukherjee et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Alternative Treatments For Melanoma: Targeting BCL-2 Family Members to De-Bulk and Kill Cancer Stem Cells

(2015) Nabanita Mukherjee et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

BH3 profiling identifies heterogeneous dependency on Bcl-2 family members in multiple myeloma and predicts sensitivity to BH3 mimetics

(2015) C Touzeau et al.   LEUKEMIA

The NOXA–MCL1–BIM axis defines lifespan on extended mitotic arrest

(2015) Manuel D. Haschka et al.   Nature Communications

Tumorsphere as an effective in vitro platform for screening anti-cancer stem cell drugs

(2015) Che-Hsin Lee et al.   Oncotarget

SOX2 regulates self-renewal and tumorigenicity of human melanoma-initiating cells

(2014) R Santini et al.   ONCOGENE

Targeting BCL-2 with the BH3 Mimetic ABT-199 in Estrogen Receptor-Positive Breast Cancer

(2013) François Vaillant et al.   CANCER CELL

Selective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia

(2013) R. Pan et al.   Cancer Discovery

HEDGEHOG-GLI Signaling Drives Self-Renewal and Tumorigenicity of Human Melanoma-Initiating Cells

(2012) Roberta Santini et al.   STEM CELLS

Synergistic Activity of Fenretinide and the Bcl-2 Family Protein Inhibitor ABT-737 against Human Neuroblastoma

(2011) H. Fang et al.   CLINICAL CANCER RESEARCH

The Combination of BH3-Mimetic ABT-737 with the Alkylating Agent Temozolomide Induces Strong Synergistic Killing of Melanoma Cells Independent of p53

(2011) Steven N. Reuland et al.   PLoS One

RNA Silencing of Mcl-1 Enhances ABT-737-Mediated Apoptosis in Melanoma: Role for a Caspase-8-Dependent Pathway

(2009) Angela M. Keuling et al.   PLoS One

BH3-only proteins Noxa, Bmf, and Bim are necessary for arsenic trioxide-induced cell death in myeloma

(2008) A. A. Morales et al.   BLOOD

Active N-Ras and B-Raf Inhibit Anoikis by Downregulating Bim Expression in Melanocytic Cells

(2008) Nathaniel B. Goldstein et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Mechanism of Synergy of N-(4-Hydroxyphenyl)Retinamide and ABT-737 in Acute Lymphoblastic Leukemia Cell Lines: Mcl-1 Inactivation

(2008) Min H. Kang et al.   JNCI-Journal of the National Cancer Institute

Oncogenic BRAFV600E inhibits BIM expression to promote melanoma cell survival

(2008) Robert A. Cartlidge et al.   Pigment Cell & Melanoma Research